# A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

> **NCT02983227** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 496 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** GDC-0853

## Key facts

- **NCT ID:** NCT02983227
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-30
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 496 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02983227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02983227, "A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02983227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*